GlassScriptPhysician profile
Angela Ahuja
NPI 1851300230
$13,900.13
in general payments reported to CMS, 2019-2025
23 companies · $11K in 2025
The $11K reported for 2025 was more than what 88% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $220 · 2020: $146 · 2021: $229 · 2022: $339 · 2023: $957 · 2024: $1,397 · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,062 · Food and Beverage: $3,882 · Education: $22.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,062.00 |
| Food and Beverage | $3,882.34 |
| Education | $22.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $9,751.80 | 2021-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $1,624.28 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Glaxosmithkline, LLC. | $693.71 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Pfizer INC. | $501.71 | 2023-2025 | |
| Amgen INC. | $205.40 | 2023-2025 | Tezspire, Tavneos |
| Takeda Pharmaceuticals U.S.A., INC. | $200.57 | 2020-2025 | Cuvitru, Eohilia, Takhzyro |
| Abbvie INC. | $165.94 | 2023-2024 | Rinvoq |
| Pharming Healthcare, INC. | $153.73 | 2022-2025 | Ruconest |
| Csl Behring | $130.49 | 2024-2025 | Haegarda, Hizentra |
| Genzyme Corporation | $74.62 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $72.37 | 2025 | |
| Kaleo, INC. | $41.73 | 2020-2024 | Auvi-Q |
| Genentech USA, INC. | $35.53 | 2019-2024 | Xolair |
| Biocryst US Sales Co., LLC | $35.34 | 2023 | Orladeyo |
| Shire North American Group INC | $33.48 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $33.27 | 2025 | Ebglyss |
| Invivyd INC | $33.07 | 2025 | Pemgarda |
| Merck Sharp & Dohme LLC | $30.21 | 2025 | Capvaxive |
| Blueprint Medicines Corporation | $20.92 | 2023 | |
| Cycle Pharmaceuticals INC | $19.16 | 2025 | Sajazir |
| Ars Pharmaceuticals Operations, INC. | $15.38 | 2025 | Neffy |
| Galderma Laboratories, L.P. | $13.74 | 2025 | Nemluvio |
| Arcutis Biotherapeutics, INC. | $13.68 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Ahuja listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.